Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Articles with Puma Biotechnology
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology Surging
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology
SEC charges former Puma biotech exec with $1.1 million in insider trading
What Happened To Puma Biotechnology?
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology - Crunchbase Company Profile & Funding
Why Shares of Puma Biotechnology Rose This Week | The Motley Fool
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
